TScan Therapeutics, Inc.
TCRX
$0.95
-$0.07-6.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.71M | -36.95M | -34.13M | -35.81M | -29.89M |
| Total Depreciation and Amortization | 767.00K | 698.00K | 678.00K | 711.00K | 1.03M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.84M | 2.60M | 2.25M | 2.43M | 1.22M |
| Change in Net Operating Assets | -359.00K | 386.00K | -6.38M | 5.26M | -279.00K |
| Cash from Operations | -32.46M | -33.27M | -37.59M | -27.41M | -27.92M |
| Capital Expenditure | -1.43M | -1.28M | -1.53M | -888.00K | -1.37M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 34.00M | 49.72M | 15.06M | 28.18M | -80.98M |
| Cash from Investing | 32.58M | 48.44M | 13.53M | 27.29M | -82.35M |
| Total Debt Issued | -- | -- | -- | 32.46M | -- |
| Total Debt Repaid | -- | -- | -- | -17.14M | -- |
| Issuance of Common Stock | 0.00 | 191.00K | -- | 378.00K | 1.23M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -75.00K | -525.00K | 30.00M | 0.00 |
| Cash from Financing | 0.00 | 116.00K | -525.00K | 45.69M | 1.23M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.00K | 15.29M | -24.58M | 45.57M | -109.04M |